fda compounding semaglutide crackdown news november 2025 The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the Compound versions of GLP-1 drugs
Description
You are on the lowest starting dose, which is intentionally subtherapeutic for weight loss
The clinical pattern shows that semaglutide works best when dosed consistently and when combined with dietary and lifestyle changes
GLP-1 medications like semaglutide and tirzepatide have produced clinical trial results previously only associated with bariatric surgery and access to these medications through medically supervised programs is now widely available
The total peptide amount does not change
Noteworthy, hyperglycemia induces the synthesis of AT1R, which plays a pivotal role in reno- and cardiovascular disease
That was new for me
